14 results about "Immunologic disease" patented technology

Provided are piperazine fused ring system derivatives of formula (I), pharma- ceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising said compounds, and uses of said compounds as polyadenosine diphosphate ribose (ADP-ribose) polymerase (PARP) inhibitors in the treatment of related diseases such as cancer, inflammation, metabolic diseases, cardiovascular diseases, immune diseases and psychiatric diseases. [Formula 1] JPEG2025503798000246.jpg20169

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The invention discloses a kit for animal immune disease detection, and relates to the technical field of animal immune disease detection.The kit comprises a kit body, an opening is formed in the front portion of the kit body, and a multifunctional side plate structure is embedded in the opening; when redundant pore plates of the elisa plate are taken out, through the multifunctional side plate structure, the side plate body is grabbed up, the bottom rubber film is pressed by fingers to make contact with the multiple cleaning abutting structures, and the corresponding number of cleaning abutting structures make contact and are jacked into the telescopic grooves of the supporting frame to stretch out; a plurality of cleaning contact structures can be stretched out by selecting a proper number of transverse and longitudinal parts according to needs, a user only needs to align an elisa plate with the plurality of stretched cleaning contact structures to be in contact with the cleaning contact structures to press down the elisa plate, redundant elisa hole plate strips are propped out of a machine shell, the elisa hole plate strips at different positions can be taken out at will, and the elisa hole plate strips are relatively convenient and do not need to be manually pressed out one by one.

The present disclosure relates, in general, to synthetic, spherical lipoprotein-like nanoparticles comprising an organic core material that provides properties that are similar to mature human HDLs and use thereof to treat disorders such as cancer or immune disorders. In various embodiments, the disclosure provides a spherical lipoprotein-like nanoparticle (HDL-NP) comprising: a core and a shell surrounding and attached to the core, wherein the core comprises a lipid conjugated organic scaffold comprising a dendritic lipid scaffold.

The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

The invention discloses a cloned hematopoietic multi-phenotype genetic big data driven cancer suppression target gene prediction method, which comprises the following steps: acquiring a cloned hematopoietic multi-phenotype genetic big data set which comprises a plurality of different cloned hematopoietic phenotypes, genetic regulation evidence and gene interaction evidence; a candidate target gene-clone hematopoietic multi-phenotype prediction matrix is constructed by analyzing genetic regulation evidence and gene interaction evidence, and the prediction matrix comprises candidate target gene data under different clone hematopoietic phenotypes and is used for evaluating the importance of each candidate target gene in different clone hematopoietic phenotypes; according to the prediction matrix, in combination with genetic regulation evidence and gene interaction evidence, performing priority ranking on candidate target genes to obtain cloned hematopoietic genetic target gene leader recommendation, and obtaining a leader recommendation target gene list; and obtaining a genetic target gene recommendation map according to the leader recommendation target gene list, and comparing the genetic target gene recommendation map with an immune disease map to obtain a list of target genes capable of being intervened.

Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1 / Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

The invention provides an immune disease risk assessment method. The method comprises the following steps: acquiring TCR sequence data of each sample in a training set and a test set; the TCR sequence data comprises data obtained by embedding an amino acid sequence of each high-expression TCR [beta] CDR3 after quality control into a high-dimensional vector through a pre-trained protein language model; obtaining the risk score of the immune disease of the corresponding object through a convolutional neural network by using the TCR sequence data of the training set and the test set; through a multi-fold cross validation training model, calculating indexes of the trained model of each fold, and selecting an optimal model as a risk prediction model of the immune disease based on the F1 value; and obtaining TCR sequence data of the detected object, and inputting the TCR sequence data into the risk prediction model for risk assessment to obtain the risk score of the immune disease of the detected object. The method focuses on a CDR3 region of a TCR beta chain, and comprehensively reflects the core effect of T cells in immune response and close association of the T cells with immune diseases.

The present invention relates to the new use of a drug for intervening with a HIF2α target. It has been found that HIF2α has an influence on Th2 cell differentiation, thereby playing a significant role in type II immune diseases, tumors, diseases caused by dysregulated Th2 / ILC2 differentiation, and aging. Furthermore, it has been validated that intervention with HIF2α can be used for the prevention and treatment of type II immune diseases and diseases caused by dysregulated Th2 / ILC2 differentiation, and for anti-tumor, anti-aging and anti-aging-related disease uses. The present invention provides a new potential target for the clinical treatment of type II immune diseases, tumors and diseases caused by dysregulated Th2 / ILC2 differentiation, and for anti-aging and anti-aging-related disease uses, and has good application prospects.